What is the appropriate dose of linaclotide (Linzess) for chronic idiopathic constipation?

Linzess Dose for CIC

For chronic idiopathic constipation in adults, start with linaclotide 145 mcg once daily, with the option to use 72 mcg once daily if tolerability is a concern or based on individual patient presentation. 1

FDA-Approved Dosing

The FDA label clearly specifies that for CIC in adults, the recommended dose is 145 mcg orally once daily, with 72 mcg once daily available as an alternative based on individual presentation or tolerability 1. This differs from the 290 mcg dose approved for IBS-C, though the 2023 AGA-ACG guidelines acknowledge that CIC and IBS-C often overlap in clinical practice 2.

Evidence Supporting Dosing Strategy

The 2023 AGA-ACG clinical practice guidelines provide a strong recommendation for linaclotide use in CIC patients who don't respond to over-the-counter agents, with moderate certainty of evidence 2. Clinical trials evaluated doses of 72 mcg, 145 mcg, and 290 mcg daily 2.

Efficacy Data:

• 145 mcg dose significantly increases complete spontaneous bowel movements (CSBMs) by 1.37 per week and spontaneous bowel movements (SBMs) by 1.97 per week compared to placebo 2
• 72 mcg dose demonstrated 13.4% responder rate versus 4.7% placebo (p<0.0001), with lower discontinuation rates due to diarrhea (2.4% vs 3.2% for 145 mcg) 3
• Both doses improve stool consistency, straining, and quality of life scores 2

Administration Instructions

Critical administration details from the FDA label 1:

• Take on an empty stomach, at least 30 minutes before the first meal of the day
• Take at approximately the same time each day
• Swallow capsule whole; do not crush or chew
• If unable to swallow: can open capsule and mix with applesauce or water (30 mL)

Dose Selection Algorithm

Start with 145 mcg for most patients, as this is the primary FDA-approved dose for CIC 1

Consider 72 mcg in these situations:

• Concern about diarrhea risk (elderly, frail patients)
• Patient preference for lower starting dose
• Previous intolerance to higher doses of secretagogues

Consider 290 mcg when:

• Patient has overlapping IBS-C features with significant abdominal pain, bloating, or discomfort 2
• Inadequate response to 145 mcg after appropriate trial

Safety Considerations

Diarrhea is the most common adverse event but is typically mild-to-moderate 2, 4:

• Discontinuation due to diarrhea: 4.0% with linaclotide vs 0.3% placebo in trials 2
• Only 4.7% discontinued in one study due to diarrhea 2
• Most diarrhea events are self-limited and occur early in treatment

Contraindications 1:

• Patients under 2 years of age (risk of serious dehydration)
• Known or suspected mechanical GI obstruction 2

Duration of Treatment

While clinical trials evaluated 12-week treatment periods, the FDA label does not specify a maximum duration 2. Long-term safety data up to 104 weeks shows consistent safety profile 4. The most common reasons for discontinuation in real-world practice are loss of efficacy and insurance barriers, not adverse events 2.

Special Populations

Older adults (≥65 years): No dose adjustment needed; descriptive data shows no clear differences in outcomes, though sample sizes were limited 2

Hepatic impairment: No dose adjustment needed (systemic absorption is negligible) 2

Clinical Pearls

• Linaclotide can be used as replacement or adjunct to OTC laxatives 2
• May provide additional benefit for abdominal bloating and discomfort beyond constipation relief 2, 5
• Response typically occurs within days of initiation 2
• If dose is missed, skip it and resume at regular time—do not double dose 1